Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (35): sc-58604

AChRα1/3/5 Antibody (35) is a rat monoclonal IgG1 antibody that detects the AChR alpha 1/3/5 protein of mouse, rat, human, Electrophorus electricus, and canine origin by immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). AChRα1/3/5 (35) antibody is available as the non-conjugated format. AChR alpha 1/3/5 proteins are integral components of the nicotinic acetylcholine receptor family, crucial for fast synaptic transmission in the nervous system. These receptors are located at the postsynaptic membrane of the neuromuscular junction, playing a vital role in muscle contraction by binding acetylcholine and facilitating ion influx through their transmembrane pore. Proper functioning of these receptors is essential for neuromuscular signaling, and mutations in the genes encoding AChRα3 and AChRα5 can lead to increased susceptibility to certain types of lung cancer, while defects in the AChRα1 gene can cause severe congenital disorders such as lethal multiple pterygium syndrome. Anti-AChR alpha 1/3/5 antibody (35) specifically targets these proteins, making this reagent invaluable for researchers studying synaptic transmission and related pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (35) References:

1. Acetylcholine receptor alpha subunit mRNA expression in human thymus: augmented expression in myasthenia gravis and upregulation by interferon-gamma.  |  Zheng, Y., et al. 1999. Clin Immunol. 91: 170-7. PMID: 10227809
2. [Study on the diagnostic significance of detecting the expression of AChR-gamma mRNA in rhabdomyosarcoma tissues].  |  Chang, B., et al. 2003. Zhonghua Bing Li Xue Za Zhi. 32: 413-6. PMID: 14633451
3. Normal distribution of presenilin-1 and nicastrin in skeletal muscle and the differential responses of these proteins after denervation.  |  Sakuma, K., et al. 2006. Biochim Biophys Acta. 1760: 980-7. PMID: 16595164
4. Development of a novel preparation method of recombinant proteoliposomes using baculovirus gene expression systems.  |  Fukushima, H., et al. 2008. J Biochem. 144: 763-70. PMID: 18836200
5. Recombinant expression of the AChR-alpha1 subunit for the detection of conformation-dependent epitopes in Myasthenia Gravis.  |  Ching, KH., et al. 2011. Neuromuscul Disord. 21: 204-13. PMID: 21195619
6. A role for the calmodulin kinase II-related anchoring protein (αkap) in maintaining the stability of nicotinic acetylcholine receptors.  |  Mouslim, C., et al. 2012. J Neurosci. 32: 5177-85. PMID: 22496563
7. Neuron specific reduction in CuZnSOD is not sufficient to initiate a full sarcopenia phenotype.  |  Sataranatarajan, K., et al. 2015. Redox Biol. 5: 140-148. PMID: 25917273
8. Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis.  |  Cui, YZ., et al. 2019. Neurosci Bull. 35: 507-518. PMID: 30796753
9. Physiological Expression of Ion Channel Receptors in Human Periodontal Ligament Stem Cells.  |  Chiricosta, L., et al. 2019. Cells. 8: PMID: 30845727
10. Association of the AChRalpha-subunit gene (CHRNA), DQA1*0101, and the DR3 haplotype in myasthenia gravis. Evidence for a three-gene disease model in a subgroup of patients.  |  Djabiri, F., et al. 1997. J Autoimmun. 10: 407-13. PMID: 9237805

The preferred Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 antibody is Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 Antibody (153): sc-65829.